News
Astra Zeneca: Wirbel um COVID-19-Impfstoff
AstraZeneca (WKN: 886455) teilte am Montag mit, dass die Nebenwirkungen seines potenziellen Corona-Impfstoffs bei älteren Menschen geringer seien. Die Wirkstoff-Hoffnung des britischen Pharmariesen
AstraZeneca: Patient erkrankt – Impfstoff-Studie gestoppt!
Rückschlag beim Corona-Impfstoff: Die britische Pharmaschmiede AstraZeneca (WKN: 886455) stoppt vorsorglich die entscheidende Studienphase. Ein Teilnehmer der UK-Studie habe Nebenwirkungen verspürt
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
Centers for Disease Control and Prevention (CDC)-recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis
AstraZeneca: Rebound in 2024 with double-digit earnings growth
U.K.-based AstraZeneca PLC (NASDAQ: AZN) is up 8.95% in the past month as investors grow optimistic about the company's improved earnings outlook for 2024. Not only are sales of cancer and
3 stocks that crushed earnings estimates and still tanked
Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case. Every earnings season, regardless of sector or industry, has its share of stocks that report
GSK is a remedy for the winter investment blahs
GSK (NYSE: GSK) is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
Global financial crises. A pandemic. Recession. Countless geopolitical conflicts.
A lot has happened over the last 10 years.
The U.S. stock market has been rattled by a range of events and yet
Drugmaker GSK: Becoming a Healthier Value Stock
Like most stocks during the dot-com bubble, GSK PLC (NYSE: GSK) partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceuti
MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
- Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19
- Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare
InterAx Biotech Announces Being the Recipient of a Highly Competitive European Grant to Fund Drug Development and Reports Financing Highlights
InterAx Biotech AG, a pharmaceutical product development company pioneering computational pharmacology for drug discovery, announces being awarded a highly competitive and prestigious grant
SYSTRAN Translate Server Version 10 Unveiled: a Major Step Toward Increasing Business Performance of Organizations Operating Internationally
Brand new Customer Experience, advanced customization tools for higher translation quality, integrated speech translation module
PARIS, FRANCE, SAN DIEGO, CA, SEOUL, SOUTH KOREA, and
Investors Push Back On Pharma Lawsuits To Thwart Medicare Negotiated Pricing
NEW YORK, NY, THURSDAY, AUGUST 31, 2023 - Today, investors released a statement voicing deep concern about lawsuits brought by pharma companies and trade groups to block the U.S. government’s
Drug Companies Impacted By Biden Rx Cost Saving Effort Boasted Of $38.7b In Profits In 2022
WASHINGTON, DC – The Biden administration has announced the first 10 prescription drugs impacted by the Inflation Reduction Act’s measures giving Medicare the power to negotiate lower prices
TECO 2030 und Partner erhalten 13,5 Mio. EUR Förderung von Horizon Europe für ein Passagierfährenprojekt
LYSAKER, Norwegen, Aug. 07, 2023 (GLOBE NEWSWIRE) -- TECO 2030 (OSE: TECO, OTCQX: TECFF, ISIN: NO0010887516) hat zusammen mit Partnern eine Förderung von HORIZON EUROPE in Höhe von 13,5 Mio. EUR
WOW EARN Wallet Offers One-Stop Shop Features, Now Available on iOS and Google Play
New York, United State, July 10th, 2023, Chainwire
WOW EARN, a new mining DeFi platform, has released a multi-chain crypto wallet on smartphones.
Launched on May 29th, WOW EARN Wallet is now
WOW EARN Secures $30 Million in Series A Funding Round to Advance Decentralized Mining
New York, United State, June 7th, 2023, Chainwire
Breaking barriers in the decentralized cryptocurrency mining sector, WOW EARN announced today the successful closure of its Series A financing
We Soda’s Expected IPO Is A Boost For London
- Industrials company, ‘We Soda’ has announced its intention to float on the LSE.
- The company manufactures natural soda ash, used in industrial processes and sustainable solutions.
- The listing
How To Survive (And Profit From) The 2023 Banking Crisis…
My warning is coming true… “When the going gets tough, you lie”… US banks are more than half a trillion dollars in the red… Banks shortchanged their clients; now they’re paying the price… Trade